Company news
Shandong Buchang Pharmaceuticals Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Progress of Capital Increase and Share Expansion of a Controlled Subsidiary to Introduce External Investors and Waiver of Preemptive Subscription Rights by the Company and Related Party Transaction
November 4, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Report for Q3 2026
October 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Signing of Technology Transfer Contract by Controlled Subsidiary
October 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Resolutions of the 59th Meeting of the 5th Board of Directors
October 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Proposed Equity Transfer by Controlled Subsidiary
October 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Change of Legal Representative of Controlled Subsidiary
October 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Receipt of the Drug Clinical Trial Approval Notice by Controlled Subsidiaries
October 28, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Providing Guarantee for Wholly-owned Subsidiary
October 28, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Implementation of Dividend Distribution for the First Half of 2026
October 27, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Progress of Proposed External Investment by Controlled Subsidiary for Establishment of Wholly-owned Subsidiary
October 23, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Approval of Marketing Authorization for Qianlie Shutong Capsules in Indonesia
October 20, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on the Profit Distribution Plan for the First Half of 2026
October 15, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Obtaining Drug Registration Certificate
October 9, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Signing of Technology Transfer Contract by Wholly-owned Subsidiary
September 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Resolutions of the 57th Meeting of the 5th Board of Directors
September 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Proposed External Investment by Controlled Subsidiary for Establishment of Wholly-owned Subsidiary
September 29, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Cooperative Investment with Private Fund
September 29, 2026
Announcement on Capital Increase and Share Expansion of Controlled Subsidiary for Introduction of External Investors, the Company's Waiver of Preemptive Subscription Rights, and Related Party Transactions
September 29, 2026
Announcement on Providing Guarantee for Controlled Subsidiary
September 28, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Proposed Capital Increase in Controlled Subsidiary
September 27, 2026
(603858)"Shandong Buchang Pharmaceuticals Co., Ltd."Announcement on Change of Legal Representative of Controlled Subsidiary
September 27, 2026
Announcement on Resolutions of the 56th Meeting of the 5th Board of Directors
September 27, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 16, 2026
Announcement on Completion of Industrial and Commercial Registration Change by Controlled Subsidiary
September 10, 2026
Announcement on Obtaining Drug Registration Certificate by Wholly‑owned Subsidiary
August 28, 2026
Semi-annual Report for 2026
August 27, 2026
Announcement on Progress of Proposed Capital Increase to Controlled Subsidiary
August 24, 2026
Announcement on Signing of Supplementary Agreement to (Entrusted) Technical Service Contract by a Controlled Subsidiary
August 21, 2026
Announcement on Completion of Industrial and Commercial Registration Change by the Controlled Subsidiary
August 19, 2026
Announcement on Receipt of Acceptance Notice for Drug Clinical Trial by Controlled Subsidiary
August 17, 2026
Announcement on Change of Legal Representative of Controlled Subsidiary
August 11, 2026
Announcement on Progress in Proposed External Investment for Establishment of a Subsidiary
August 5, 2026
Announcement on Completion of Industrial and Commercial Change Registration by Wholly-owned Subsidiary
August 3, 2026
Announcement on Withdrawal of Drug Registration Application by Controlled Subsidiary
July 29, 2026
Announcement on Proposed External Investment for Establishment of a Subsidiary
July 28, 2026
Announcement on Change of Drug Production License of Wholly-owned Subsidiary
July 24, 2026
Announcement on Signing of (Entrusted) Technology Development Contract by Wholly-owned Subsidiary
July 23, 2026
Announcement on the Proposed Capital Increase in a Controlled Subsidiary
July 21, 2026
Announcement on the Completion of Registration of Change in Medical Device Business License by a Controlled Subsidiary
July 16, 2026
Announcement on the Adjustment of the Company's Products in the "National Essential Medicines List"
July 10, 2026
Announcement on Resolutions of the 51st Meeting of the 5th Board of Directors
June 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 26, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
June 22, 2026
Announcement on Progress in on Proposed Capital Increase in Holding Subsidiary and Change in Name of Holding Subsidiary
June 18, 2026
Announcement on Completion of Registration of Change in Business License for Medical Device by the Holding Subsidiary
June 10, 2026
Announcement on Progress in Holding Subsidiary's Proposal to Invest in the Establishment of a External Subsidiary
June 9, 2026
Announcement on Change of Drug Production License of Wholly-owned Subsidiary
June 8, 2026
Announcement on Initially Repurchasing Shares through Call Auction
June 2, 2026
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Limit Concerning Repurchase
June 1, 2026
Announcement on Progress in Proposed Transfer of Equity in a Holding Subsidiary and Waiver of the Right of First Refusal
May 29, 2026